These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37287176)

  • 1. Bacillus Calmette-Guérin Packaged for Percutaneous Vaccination Can Be Safely Used for Intravesical Instillation in Patients with Urothelial Carcinoma of the Bladder.
    Masic S; Srivastava A; Kloth D; Needleman R; Bloom E; Uzzo RN; Amoroso C; Lee R; Greenberg R; Smaldone M; Viterbo R; Joshi S; Chen DYT; Uzzo RG; Kutikov A
    Urol Pract; 2020 Nov; 7(6):487-489. PubMed ID: 37287176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Int J Urol; 2022 Aug; 29(8):867-875. PubMed ID: 35577361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of infectious thoracic aortic aneurysm after intravesical Bacillus Calmette-Guérin instillation therapy for a superficial bladder cancer.
    Koterazawa S; Watanabe J; Uemura Y; Uegaki M; Shirahase T; Taki Y
    Urol Case Rep; 2021 May; 36():101574. PubMed ID: 33552915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.
    Syed S; Rahman M; Israr A; Anwar M; Khatroth S; Safi D; Kamran A
    SAGE Open Med; 2023; 11():20503121231160408. PubMed ID: 36949824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
    Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
    J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
    Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
    J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.
    Nazmifar M; Williams C; Naser-Tavakolian A; Heard J; Rosser C; Theodorescu D; Ahdoot M
    J Urol; 2023 Jan; 209(1):32-48. PubMed ID: 36067380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome.
    Waked R; Choucair J; Chehata N; Haddad E; Saliba G
    J Clin Tuberc Other Mycobact Dis; 2020 May; 19():100149. PubMed ID: 32099909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature.
    Alvarez-Múgica M; Gómez JM; Vázquez VB; Monzón AJ; Rodríguez JM; Robles LR
    J Med Case Rep; 2009 Sep; 3():7323. PubMed ID: 19918272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
    Miyamoto T; Miyake M; Toyoshima Y; Fujii T; Shimada K; Nishimura N; Iida K; Nakahama T; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Ohbayashi C; Fujimoto K
    Int J Urol; 2021 Jul; 28(7):720-726. PubMed ID: 33734503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter Study.
    Numakura K; Kobayashi M; Ishida T; Okane K; Suzuki K; Shimoda N; Suzuki T; Kumazawa T; Sasaki R; Fukuda H; Kashima S; Yamamoto R; Koizumi A; Nara T; Kanda S; Huang M; Saito M; Narita S; Inoue T; Tsuchiya N; Habuchi T
    Eur Urol Focus; 2022 Nov; 8(6):1666-1672. PubMed ID: 35717522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.
    Johnson MH; Nepple KG; Peck V; Trinkaus K; Klim A; Sandhu GS; Kibel AS
    J Urol; 2013 Apr; 189(4):1268-74. PubMed ID: 23123375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.